Sarepta shakes up C-suite as they prepare to test FDA on Duchenne again
After slowly losing executives over the last two years, Sarepta has announced a host of changes at its highest level.
Sarepta on Monday announced a new CFO, chief commercial officer, CSO and general counsel, effectively giving the biotech a new C-suite in a single press release.
Sudden and sweeping executive changes aren’t generally a great indicator for a company’s health, but the circumstances around Sarepta’s latest changes are relatively unique. The company hasn’t had a CSO since 2018, when Guriq Basi departed after a one-year tenure. Their longtime chief commercial officer, Bo Cumbo, recently spun out on his own, raising $107 million for a new gene therapy play. And their longtime CFO and CBO Sandy Mahatme “retired” in June for what turned out to be an opportunity to help run Bob Nelsen’s $800 million startup Resilience.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.